the Private Lecture Series

The myelodysplastic syndromes (MDS) are recognized as a growing disease burden in oncology care within the United States. For the first time in the history of this disease, physicians have access to a therapeutic agent with the capacity to impact the natural history of the disease. Understanding the selection of patients, proper counseling on side effects, and the potential for development of combination treatments is paramount for optimizing patient outcomes and further drug development for the treatment of MDS.

Steven D. Gore, MD
Johns Hopkins Medical Institutions

Alan F. List, MD
H. Lee Moffitt Cancer Center and Research Institute